Top Industry Leaders in the Meningococcal Vaccines Market
Meningococcal Vaccines Key Companies.jpg" width="600" height="300">
Disclaimer: List of key companies in no particular orderLatest Meningococcal Vaccines Companies Update
-
October 2023: The US Food and Drug Administration (FDA) has authorized Pfizer's Penbraya as the first pentavalent vaccination that protects people between the ages of ten and twenty-five against the five most frequent serogroups that cause meningococcal illness. Meningococcal disease is a rare but dangerous infection that can cause death in as little as 24 hours and leave survivors with severe, lifelong disability. As of right now, Pfizer is authorized to market two vaccines to ward against meningococcal group B, known as Trumenba, and groups A, C, W, and Y, known as Nimenrix. By lowering the total number of doses required to be adequately protected against the five serogroups, Penbraya streamlines the meningococcal vaccination schedule and may result in a higher immunization rate among adolescents and young adults. Penbraya mixes the components from both vaccines.
-
March 2023: GSK announced encouraging trial findings for its eagerly awaited combination meningitis vaccine, almost three years after dosing the first patient in a phase 3 study. The shot targets meningitis and blood poisoning caused by the A, B, C, W, and Y families of meningococcal bacteria. It combines the two authorized vaccines from GSK, Menveo and Bexsero. Nearly all occurrences of invasive meningococcal disease (IMD) worldwide are caused by serogroups A, B, C, W, and Y, according to a statement from GSK. In order to be protected against all five groups, one must currently receive four shots from two different vaccinations in the United States. GSK said that the experiment, which included healthy participants aged 10 to 25, achieved its goals with the vaccine candidate. The vaccination produced a “clinically meaningful immune response,” matching up to Bexsero and Menveo.
List of meningococcal vaccines Key companies in the market
- Pfizer Inc (US)
- Novartis AG (Switzerland)
- Sanofi S.A.(France)
- Serum Institute of India Pvt. Ltd (India)
- GlaxoSmithKline plc (UK)
- Merck & Co., Inc (US)
- Incepta Pharmaceuticals Ltd (Bangladesh)
- BIO-MED (US)
- Walvax Biotechnology Co., Ltd (China)
- Bio-Manguinhos (Brazil)
